Mar 23, 2021 / 03:00PM GMT
John Temperato - 9 Meters Biopharma, Inc. - President, CEO & Director
We brought 9 Meters together less than a year ago with the goal in mind of creating a company with an unwavering commitment to improving the lives of patients with debilitating GI disorders. As we go through our story today, we hope you will see we are truly on our way.
Here is the obligatory forward-looking statement with the appropriate safe harbors. Regarding our R&D Day agenda, you'll also get a quick introduction from myself, followed by an SBS overview and management from Dr. Patrick Griffin, our Chief Medical Officer. That will be followed by a topic called Clinical Impact of Chronic Diarrhea in SBS Patients by Carol Rees Parrish, who literally wrote the book, which you'll see. We will then go back to Patrick Griffin in terms of a paradigm shift from GLP-2s to GLP-1s. We will then recap our Phase Ib/IIa results and provide some additional data. And then we're very pleased, and most importantly, we believe, to share our clinical and regulatory path forward.
As I think you all saw in the press release, the
9 Meters Biopharma Inc Host KOL Perspectives on Short Bowel Syndrome & NM-002 Program Update Corporate Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers